Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on March 7, 2019, covering events occurring on March 1, 2019. The registrant is an emerging growth company incorporated in Delaware. The filing primarily addresses corporate governance changes regarding executive compensation and the expiration of outstanding warrants.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. Specific financial figures disclosed relate only to executive compensation and warrant terms:
- Executive Compensation: A one-time retention payment of $18,465.38 to the Chief Financial Officer (CFO), Russell Skibsted.
- Recurring Compensation: $1,500 per week for one day of service; excess services billed at $175 per hour.
- Warrant Details: 2,000,000 outstanding warrants with an exercise price of $2.50 per share.
Material Changes
The filing reports two material changes effective March 1, 2019:
- Compensation Structure: Transition from reimbursing a former parent company (BioTime, Inc.) for the CFO's services to a direct compensation agreement with Mr. Skibsted. Previously, the CFO was compensated by BioTime and participated in BioTime benefit plans; under the new agreement, he receives direct payment but is excluded from employee benefit plans (retirement, health, vacation, etc.).
- Warrant Expiration: Confirmation that outstanding common stock purchase warrants will expire at 5:00 p.m. New York time on March 18, 2019.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or operational outlook. It includes a standard disclaimer regarding forward-looking statements, noting that actual results may differ materially due to risk factors detailed in periodic SEC reports. The document highlights that the summary of the compensation agreement is not complete and refers investors to the full agreement to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2019.
Investor Verification Checklist
- Verify the full terms of the CFO compensation agreement in the upcoming Form 10-Q exhibit.
- Confirm the status of the 2,000,000 warrants following the March 18, 2019 expiration date.
- Review the company's liquidity position in the next quarterly report, as this 8-K does not disclose cash balances or debt levels.
- Note the distinction between the registrant name (AgeX Therapeutics, Inc.) and the metadata provided (Serina Therapeutics, Inc.).